3-(2-METHYL-4OXO-4H-BENZO[G]QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE | 1135009-16-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-(2-METHYL-4OXO-4H-BENZO[G]QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE
• 英文别名: 3-(2-Methyl-4-oxobenzo[g]quinazolin-3-yl)piperidine-2,6-dione
• CAS: 1135009-16-3
• 化学式: C₁₈H₁₅N₃O₃
• 分子量: 321.335
• InChiKey: NUYWSEMWUWUCBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  78.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-氨基-2,6-哌啶二酮盐酸盐 、 乙酰氯 、 3-氨基-2-萘甲酸 在 咪唑 、 亚磷酸三苯酯 作用下， 以 乙腈 为溶剂， 反应 22.0h， 以79%的产率得到3-(2-METHYL-4OXO-4H-BENZO[G]QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE
  参考文献：
  名称：

  6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same

  摘要：

  提供了喹唑啉酮化合物，以及其药用盐、溶剂合物、包合物、立体异构体和前药。公开了这些化合物的使用方法和药物组合物。

  公开号：

  US20090093504A1

文献信息

• 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME
  申请人：Muller George W.

  公开号：US20130289274A1

  公开（公告）日：2013-10-31

  Provided are quinazolinone compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

  提供了喹唑酮类化合物及其药学上可接受的盐、溶剂合物、包合物、立体异构体和前药。公开了这些化合物的使用方法和制药组合物。
• Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
  申请人：Celgene Corporation

  公开号：US10034872B2

  公开（公告）日：2018-07-31

  Methods of treating, preventing and/or managing multiple myeloma are disclosed. Specific methods encompass the administration of an immunomodulatory compound, e.g., lenalidomide or pomalidomide with an anti-CS1 antibody, e.g., elotuzumab in patients who have received autologous stem cell transplantation.

  本文公开了治疗、预防和/或控制多发性骨髓瘤的方法。具体方法包括在接受了自体干细胞移植的患者中使用免疫调节化合物，如来那度胺或泊马度胺与抗CS1抗体，如艾洛妥珠单抗。
• METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY
  申请人：Signal Pharmaceuticals, LLC.

  公开号：US20140314753A1

  公开（公告）日：2014-10-23

  Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of a 5-Substituted Quinazolinone Compound to a patient having a cancer.
• METHODS FOR TREATING CANCER USING COMBINATION THERAPY
  申请人：CELGENE CORPORATION

  公开号：US20140328832A1

  公开（公告）日：2014-11-06

  Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a substituted quinazolinone compound and an effective amount of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide to a patient having a cancer.
• TREATMENT OF CANCER CHARACTERIZED BY GENE MUTATIONS
  申请人：SIGNAL PHARMACEUTICALS, LLC

  公开号：US20150099754A1

  公开（公告）日：2015-04-09

  Provided herein are methods for treating and/or preventing a cancer in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having cancer characterized by particular gene mutation(s) or variant(s) relative to the genes of a biological wild-type sample.